Changes in Hong Kong stocks | Corning Jerry Pharmaceutical-B (09966) rose more than 6% JSKN003 for treating PROC and obtained FDA breakthrough therapy certification

The Zhitong Finance App learned that Corning Jerry Pharmaceutical-B (09966) rose more than 6% in the morning. As of press release, it had risen 6.05% to HK$11.57, with a turnover of HK$12.3817 million.

According to the news, Corning Jerry Pharmaceuticals announced that JSKN003 has been granted breakthrough therapy certification by the US Food and Drug Administration (FDA) to treat adult patients with advanced or metastatic human epidermal growth factor receptor 2 expression (IHC 1+, 2+, and 3+) platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who have previously been treated with bevacizumab.

Guojin Securities released a research report stating that JSKN003 is the company's self-developed HER2 dual antibody ADC. Phase III clinical trials of the product are progressing in an orderly manner in China: in the overall population of platinum-resistant ovarian cancer, its efficacy and safety have shown superior characteristics to Enhertu, and it is expected that data reading and production will be completed in 2027; it is expected that 2L HER2 positive breast cancer NDA will be submitted to CDE in 2026; it is expected that 2L HER2 positive metastatic colorectal cancer clinical trial will be initiated in October 2025. period JSKN003 expects the 27/28/29 sales share to be 0.05/0.57 billion yuan.